Achmea Investment Management B.V. Has $433,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Achmea Investment Management B.V. grew its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 31.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,143 shares of the company’s stock after purchasing an additional 754 shares during the quarter. Achmea Investment Management B.V.’s holdings in Neurocrine Biosciences were worth $433,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vestal Point Capital LP bought a new position in Neurocrine Biosciences during the 4th quarter worth $105,408,000. Norges Bank acquired a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at about $35,731,000. Vanguard Group Inc. raised its position in shares of Neurocrine Biosciences by 2.3% during the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock worth $1,369,673,000 after acquiring an additional 220,598 shares during the last quarter. Iron Triangle Partners LP bought a new stake in Neurocrine Biosciences in the first quarter valued at approximately $30,342,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Neurocrine Biosciences by 40.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock valued at $97,828,000 after acquiring an additional 203,934 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NBIX. Oppenheimer boosted their price target on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Cantor Fitzgerald decreased their price target on Neurocrine Biosciences from $170.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, August 29th. UBS Group boosted their price objective on Neurocrine Biosciences from $174.00 to $193.00 and gave the company a “buy” rating in a research note on Tuesday, May 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Thursday, August 29th. Finally, Wedbush reiterated an “outperform” rating and issued a $152.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, May 29th. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $162.20.

Insiders Place Their Bets

In other news, insider Julie Cooke sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $140.19, for a total value of $1,401,900.00. Following the sale, the insider now owns 18,202 shares of the company’s stock, valued at $2,551,738.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total transaction of $40,322.10. Following the completion of the transaction, the insider now owns 6,607 shares of the company’s stock, valued at approximately $975,853.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Julie Cooke sold 10,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $140.19, for a total value of $1,401,900.00. Following the sale, the insider now owns 18,202 shares in the company, valued at $2,551,738.38. The disclosure for this sale can be found here. Insiders sold 71,798 shares of company stock worth $10,676,096 over the last quarter. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Trading Up 0.8 %

NASDAQ:NBIX opened at $122.25 on Friday. Neurocrine Biosciences, Inc. has a 12 month low of $103.63 and a 12 month high of $157.98. The firm’s 50 day moving average is $140.95 and its 200 day moving average is $138.59. The stock has a market capitalization of $12.34 billion, a PE ratio of 33.68 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The firm had revenue of $590.20 million for the quarter, compared to analysts’ expectations of $545.98 million. During the same period in the prior year, the company earned $0.95 EPS. The firm’s quarterly revenue was up 30.4% on a year-over-year basis. Research analysts predict that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.